Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.42 |
| ▸ | LTA4H | P09960 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL515527 | 0.84 | MME (0.44) | MMELTA4HSMN1; SMN2RAB9A | |
| SCHEMBL3725757 | 0.84 | MME (0.44) | MMELTA4HSMN1; SMN2RAB9A | |
| SCHEMBL14742983 | 0.81 | MME (0.45) | MMELTA4HSMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL23029293 | 0.78 | USP2 (0.30) | SMN1; SMN2USP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL21235180 | 0.78 | USP2 (0.30) | SMN1; SMN2USP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL23029153 | 0.78 | USP2 (0.30) | SMN1; SMN2USP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL24230004 | 0.78 | USP2 (0.30) | SMN1; SMN2USP2ALDH1A1LMNACYP1A2 | |
| SCHEMBL24230134 | 0.76 | — | — | |
| SCHEMBL28871675 | 0.76 | MME (0.41) | MMELTA4HSMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL997755 | 0.76 | MME (0.42) | MMELTA4HSMN1; SMN2USP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7015306-B2 | Labeled neurotensin derivatives | BIOSYNTHEMA, INC. (US) | 2006-03-21 | — | — | US | claimed |
| US-20050191240-A1 | Peptide analogs of neurotensin resistant to enzymatic degradation and retain high binding affinity for neurotensin receptors; metal chelating group on one end; replacing Arg8 with Gly(PipAm) ((N-amidinopiperidinyl)glycine) for example; useful for diagnostic and therapeutic purposes | ADVANCED ACCELERATOR APPLICATIONS USA, INC. | 2005-09-01 | — | — | US | claimed |
| EP-1194444-A2 | LABELED NEUROTENSIN DERIVATIVES WITH IMPROVED RESISTANCE TO ENZYMATIC DEGRADATION | BioSynthema Inc. (US) | 2002-04-10 | — | — | EP | claimed |
| WO-2000078796-A2 | LABELED NEUROTENSIN DERIVATIVES WITH IMPROVED RESISTANCE TO ENZYMATIC DEGRADATION | MALLINCKRODT INC. (US) | 2000-12-28 | — | — | WO | claimed |
| US-20250270255-A1 | CASPASE-2 INHIBITOR COMPOUNDS | KINTSUGI THERAPEUTICS S L (ES) | 2025-08-28 | — | — | US | disclosed |
| EP-4363436-A1 | CASPASE-2 INHIBITOR COMPOUNDS | Kintsugi Therapeutics S.L. (ES) | 2024-05-08 | — | — | EP | disclosed |
| CN-117940444-A | Caspase-2 inhibitor compounds | 金特速吉医疗有限责任公司 | 2024-04-26 | — | — | CN | disclosed |
| WO-2023275357-A1 | CASPASE-2 INHIBITOR COMPOUNDS | Kintsugi Therapeutics S.L. (ES) | 2023-01-05 | — | — | WO | disclosed |
| EP-4112631-A1 | CASPASE-2 INHIBITOR COMPOUNDS | Kintsugi Therapeutics S.L. (ES) | 2023-01-04 | — | — | EP | disclosed |
| US-11302421-B2 | Data storage using peptides | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2022-04-12 | — | — | US | disclosed |
| US-20210090688-A1 | Data storage using peptides | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2021-03-25 | — | — | US | disclosed |
| US-7015306-B2 | Labeled neurotensin derivatives | BIOSYNTHEMA, INC. (US) | 2006-03-21 | — | — | US | disclosed |
| US-20050191240-A1 | Peptide analogs of neurotensin resistant to enzymatic degradation and retain high binding affinity for neurotensin receptors; metal chelating group on one end; replacing Arg8 with Gly(PipAm) ((N-amidinopiperidinyl)glycine) for example; useful for diagnostic and therapeutic purposes | ADVANCED ACCELERATOR APPLICATIONS USA, INC. | 2005-09-01 | — | — | US | disclosed |
| EP-1194444-A2 | LABELED NEUROTENSIN DERIVATIVES WITH IMPROVED RESISTANCE TO ENZYMATIC DEGRADATION | BioSynthema Inc. (US) | 2002-04-10 | — | — | EP | disclosed |
| WO-2000078796-A2 | LABELED NEUROTENSIN DERIVATIVES WITH IMPROVED RESISTANCE TO ENZYMATIC DEGRADATION | MALLINCKRODT INC. (US) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270255-A1 | CASPASE-2 INHIBITOR COMPOUNDS | CASP2, CASP1, CASP3 | MME 947/4885LTA4H 1981/4885SMN1; SMN2 605/4885 |
| US-20050191240-A1 | Peptide analogs of neurotensin resistant to enzymatic degradation and retain high binding affinity for neurotensin receptors; metal chelating group on one end; replacing Arg8 with Gly(PipAm) ((N-amidinopiperidinyl)glycine) for example; useful for diagnostic and therapeutic purposes | ANPEP, DNPEP, NTSR1 | MME 36/4885LTA4H 2664/4885SMN1; SMN2 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.